Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years

von Herold, Kevan C
Veröffentlicht in: Clinical immunology (Orlando, Fla.) (2009)